Quantitative BRAF p.V600E mutation monitoring in cerebrospinal fluid cell-free DNA reflects therapeutic response to BRAF/MEK inhibitors in papillary craniopharyngioma: a report of two cases.

Abstract excerpt

Papillary craniopharyngioma (PCP), molecularly defined by the BRAF p.V600E mutation in > 90% of cases, is a highly specific target for BRAF/MEK inhibitor therapy, based on dramatic radiologic responses observed in clinical trials. However, the utility of real-time molecular monitoring remains largely unexplored. Here, we present two patients with BRAF p.V600E-mutant PCP who achieved exceptional tumor volume...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell-Free Nucleic Acids
• Share to Craniopharyngioma